Inactive Instrument

Vital Therapies Inc Stock price Nasdaq

Equities

US92847R1041

Biotechnology & Medical Research

Sales 2024 * - Sales 2025 * - Capitalization 119M
Net income 2024 * -92M Net income 2025 * -105M EV / Sales 2024 * -
Net cash position 2024 * 33.12M Net Debt 2025 * 55.55M EV / Sales 2025 * -
P/E ratio 2024 *
-1.32 x
P/E ratio 2025 *
-1.33 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.28%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Vital Therapies Inc

Managers TitleAgeSince
Chief Executive Officer 55 16-12-31
Director of Finance/CFO 56 19-11-30
Chief Tech/Sci/R&D Officer 51 16-12-31
Members of the board TitleAgeSince
Director/Board Member 61 19-11-18
Director/Board Member 75 19-10-10
Director/Board Member 57 19-03-31
More insiders
Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company’s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.
Calendar
2024-04-09 - R&D Day
More about the company
  1. Stock
  2. Equities
  3. Stock Immunic, Inc.
  4. Stock Vital Therapies Inc - Nasdaq